RxDoctor Payments Data

Breana Bevan

Family · Newtown, PANPI 1598358087

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 41 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$545
  • Novo Nordisk$368
  • Novartis$54
  • Lilly USA, LLC$46
  • AbbVie$43
  • Exact Sciences$40
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,114100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen15$545
Novo Nordisk16$368
Novartis2$54
Lilly USA, LLC2$46
AbbVie3$43
Exact Sciences2$40
Pfizer1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,683
Medicare patients
77
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$35,531
JardianceEmpagliflozin17$27,772
XareltoRivaroxaban20$23,680
MounjaroTirzepatide16$22,182
OzempicSemaglutide14$16,570
MyrbetriqMirabegron12$6,184
SynthroidLevothyroxine Sodium23$2,919
Atorvastatin Calcium127$2,492
Rosuvastatin Calcium118$2,187
Valsartan33$1,173
Tamsulosin Hcl46$1,164
Pantoprazole Sodium53$997
Losartan Potassium57$846
Metoprolol Succinate35$844
Levothyroxine Sodium67$832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$35,53123 claims
Lilly USA, LLCMounjaro$46$22,18216 claims
Novo NordiskOzempic$368$16,57014 claims
AbbVieSynthroid$43$2,91923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Newtown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →